Compounds > mi-219
Page last updated: 2024-10-15

mi-219

Description

MI-219: an MDM2 inhibitor; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID156596490
MeSH IDM0577087

Synonyms (7)

Synonym
mi-219
mi 219 [who-dd]
1201143-87-4
mi219
y264g2v2nc ,
spiro(3h-indole-3,3'-pyrrolidine)-5'-carboxamide, 6-chloro-4'-(3-chlorophenyl)-n-((3s)-3,4-dihydroxybutyl)-2'-(2,2-dimethylpropyl)-5-fluoro-1,2-dihydro-2-oxo-, hydrochloride (1:1), (2'r,3s,4'r,5'r)
unii-y264g2v2nc

Pharmacokinetics

ExcerptReference
" To estimate half-life of MI-219, plasma concentration-time profile in humans was predicted using kallynochron and apolysichron time transformation (Dedrick plots) and normalization with MRT and Vdss (Wajima's method)."( Preclinical pharmacokinetics of MI-219, a novel human double minute 2 (HDM2) inhibitor and prediction of human pharmacokinetics.
McEachem, D; Sun, D; Sun, W; Wang, S; Yang, Y; Yu, LX; Yu, S; Yu, Y; Zheng, N; Zou, P, 2012)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (7)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (14.29)29.6817
2010's6 (85.71)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other7 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
nutlin-3a
nutlin 3: an MDM2 antagonist; structure in first source		2.830stilbenoid
sar405838
SAR405838: an inhibitor of the interaction of MDM2 and p53; has antineoplastic activity; structure in first source		2.5320
ConditionIndicatedRelationship StrengthStudiesTrials
Atypical Lipomatous Tumor
[description not available]		02.1310
Local Neoplasm Recurrence
[description not available]		02.1310
Liposarcoma
A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)		02.1310
Thrombopenia
[description not available]		02.1310
Thrombocytopenia
A subnormal level of BLOOD PLATELETS.		02.1310
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.5420
Cancer of Prostate
[description not available]		02.1310
Prostatic Neoplasms
Tumors or cancer of the PROSTATE.		02.1310
Granulocytic Leukemia, Chronic
[description not available]		02.1510
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.		02.1510
B-Cell Lymphoma
[description not available]		07.0710
Lymphoma, B-Cell
A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.		02.0710
Benign Neoplasms
[description not available]		02.0410
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		02.0410